These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 31183224)
1. The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma. Takakuwa T; Otomaru I; Araki T; Miura A; Fujitani Y; Mochizuki Y; Miyagi Y; Senzaki H; Yamamura R Case Rep Hematol; 2019; 2019():1816287. PubMed ID: 31183224 [TBL] [Abstract][Full Text] [Related]
2. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
3. Carfilzomib. Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635 [TBL] [Abstract][Full Text] [Related]
4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768 [TBL] [Abstract][Full Text] [Related]
6. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ; Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268 [TBL] [Abstract][Full Text] [Related]
8. Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma. Yang EH; Courtney C; Garg V; Fradley MG; Schiller GJ Cardiooncology; 2018; 4():2. PubMed ID: 32154003 [TBL] [Abstract][Full Text] [Related]
9. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Zou Y; Ma X; Yu H; Hu C; Fan L; Ran X Oncotarget; 2017 Jun; 8(24):39805-39817. PubMed ID: 27458170 [TBL] [Abstract][Full Text] [Related]
10. Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Tantawy M; Chekka LM; Huang Y; Garrett TJ; Singh S; Shah CP; Cornell RF; Baz RC; Fradley MG; Waheed N; DeRemer DL; Yuan L; Langaee T; March K; Pepine CJ; Moreb JS; Gong Y Front Cardiovasc Med; 2021; 8():645122. PubMed ID: 33996940 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484 [TBL] [Abstract][Full Text] [Related]
12. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Uysal A; Akad Soyer N; Özkan M; Şahin F; Vural F; Töbü M; Tombuloğlu M; Saydam G Turk J Med Sci; 2018 Feb; 48(1):80-83. PubMed ID: 29479960 [TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Kastritis E; Laina A; Georgiopoulos G; Gavriatopoulou M; Papanagnou ED; Eleutherakis-Papaiakovou E; Fotiou D; Kanellias N; Dialoupi I; Makris N; Manios E; Migkou M; Roussou M; Kotsopoulou M; Stellos K; Terpos E; Trougakos IP; Stamatelopoulos K; Dimopoulos MA Leukemia; 2021 May; 35(5):1418-1427. PubMed ID: 33589757 [TBL] [Abstract][Full Text] [Related]
15. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M; Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405 [TBL] [Abstract][Full Text] [Related]
16. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Chari A; Stewart AK; Russell SD; Moreau P; Herrmann J; Banchs J; Hajek R; Groarke J; Lyon AR; Batty GN; Ro S; Huang M; Iskander KS; Lenihan D Blood Adv; 2018 Jul; 2(13):1633-1644. PubMed ID: 29991494 [TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. Xu W; Sun X; Wang B; Guo H Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498 [TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580 [TBL] [Abstract][Full Text] [Related]